Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
InnoCan Pharma Corporation is a pharmaceutical technology company focused on the research, development, and commercialization of cannabidiol (CBD)-based drug delivery platforms and pharmaceutical products. The company operates at the intersection of the biopharmaceutical, drug delivery, and cannabinoid therapeutics industries, with an emphasis on improving the pharmacokinetics and therapeutic efficacy of CBD through proprietary formulation technologies. Its activities are primarily pre-commercial and research-driven, with revenue generation not yet material based on publicly available filings.
The company’s core focus is the development of long-acting injectable and topical CBD formulations designed for chronic pain management and other medical indications. InnoCan’s strategic positioning centers on intellectual property around sustained-release delivery systems, which differentiates it from consumer-focused CBD companies. Founded in 2017 and publicly listed in Canada, the company has evolved from early-stage formulation research into a clinical-stage organization pursuing regulatory pathways for pharmaceutical-grade CBD products.
Business Operations
InnoCan Pharma’s operations are organized around research and development rather than traditional commercial business segments. Its primary activities include preclinical studies, clinical trials, and intellectual property development related to CBD-loaded liposome platforms. The company’s lead technology is a proprietary liposomal drug delivery system intended to enable prolonged CBD release following injection, which is being evaluated for indications such as chronic pain.
Operationally, the company conducts R&D through InnoCan Israel Ltd., which serves as its scientific and formulation development hub, while InnoCan Pharma USA Inc. supports regulatory strategy, business development, and potential commercialization in the United States. The company does not currently report meaningful commercial revenue, and its funding has historically been derived from public equity offerings and private placements as disclosed in Canadian securities filings.
Strategic Position & Investments
InnoCan Pharma’s strategic direction is centered on advancing its injectable CBD drug candidates through clinical development and securing regulatory approval, particularly under U.S. Food and Drug Administration pathways. Growth initiatives emphasize expanding its intellectual property portfolio, progressing human clinical trials, and establishing partnerships with pharmaceutical or biotechnology companies for later-stage development or commercialization.
The company has not disclosed any major acquisitions or controlling investments in unrelated businesses. Its investment focus remains internal, directed toward R&D infrastructure, clinical studies, and patent filings covering drug delivery technologies and therapeutic applications of CBD. Public disclosures indicate involvement in emerging pharmaceutical delivery technologies rather than diversification into non-core sectors.
Geographic Footprint
InnoCan Pharma operates primarily across Israel and North America, with its corporate headquarters located in Canada. Its research and development activities are concentrated in Israel, leveraging the country’s pharmaceutical research ecosystem and academic collaborations. Regulatory and capital markets activities are primarily aligned with Canada and the United States.
The company’s international presence is limited but strategically oriented toward jurisdictions with established pharmaceutical regulatory frameworks. While InnoCan does not currently report commercial operations across multiple continents, its intellectual property strategy and regulatory ambitions are designed to support future global pharmaceutical distribution pending successful clinical and regulatory outcomes.
Leadership & Governance
InnoCan Pharma is led by an executive team with experience in pharmaceuticals, finance, and biotechnology operations. The leadership emphasizes a science-driven strategy focused on clinical validation, regulatory compliance, and long-term value creation through proprietary drug delivery technologies. Corporate governance follows Canadian public company standards, with oversight by a board of directors as disclosed in regulatory filings.
Key executives include:
- Iris Bincovich – Chief Executive Officer
- David Marmor – Chief Financial Officer
- Adam Levy – Chief Operating Officer
Public sources consistently identify the Chief Executive Officer and Chief Financial Officer; however, certain executive role definitions and tenure details beyond these positions are not uniformly disclosed across filings. Data inconclusive based on available public sources.